Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm

Allogeneics Still Waiting For Breakthrough

Executive Summary

Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors. 

You may also be interested in...



KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts

Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.

Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio

AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.

GSK Poaches New Vaccines R&D Chief From Pfizer

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel